There are 30 resources available
1O - Inducible T cell co-stimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and combination with pembrolizumab: Preliminary results from INDUCE-1 expansion cohorts in head and neck squamous cell carcinoma (HNSCC)
Presenter: Christophe Le Tourneau
Session: Proffered Papers 1: Immunotherapy
Resources:
Abstract
5P - Association between baseline tumor size and outcome in patients treated with next-generation immunoncology agents
Presenter: Paolo Tarantino
Session: Poster Display & Cocktail
Resources:
Abstract
6P - Targeting leukemic stem cells using humanized chimeric immunotoxin
Presenter: Madhumathi Jayaprakasam
Session: Poster Display & Cocktail
Resources:
Abstract
7P - Proteomics plus RNA-seq in advanced melanoma samples treated with anti-PD1 immunotherapy unravel resistance mechanisms
Presenter: Guillermo Prado
Session: Poster Display & Cocktail
Resources:
Abstract
10P - In vitro and in vivo cytolethal and antitumor effects of a novel fusion protein targeting IL-24 toward breast cancer cells
Presenter: Ali Jahanian-Najafabadi
Session: Poster Display & Cocktail
Resources:
Abstract
11P - Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
Presenter: Eric Angevin
Session: Poster Display & Cocktail
Resources:
Abstract
12P - IL-18 improves the anti-cancer immunity of human gamma delta T cells against prostate cancer
Presenter: Mohanad Nada
Session: Poster Display & Cocktail
Resources:
Abstract
13P - A mitigation of breast cancer-induced immune-suppressive tumor microenvironment through curbing miR-155/IL-10/TNF-α loop using a novel quercetin derivative
Presenter: Rana Youness
Session: Poster Display & Cocktail
Resources:
Abstract
14P - Comparison of the predictive power of survival of the Royal Marsden Score, the GRIM score and the LIPI score in phase I trial patients
Presenter: Eduardo Castanon Alvarez
Session: Poster Display & Cocktail
Resources:
Abstract
20P - Interim safety and efficacy results of a phase II clinical trial on trametinib and low-dose dabrafenib in patients with advanced BRAFV600 wild-type melanoma
Presenter: Gil Awada
Session: Poster Display & Cocktail
Resources:
Abstract
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.